Tags

Type your tag names separated by a space and hit enter

Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
J Alzheimers Dis. 2012; 29(2):361-71.JA

Abstract

Recent evidence suggests that soluble oligomeric amyloid-β (Aβ) assemblies are critically involved in the pathogenesis of Alzheimer's disease (AD). We have generated a conformation-dependent monoclonal antibody (9D5) that selectively recognizes low-molecular weight AβpE3 oligomers, and demonstrated its diagnostic and therapeutic potential. Here, we further characterize the specificity of this antibody by evaluating a spectrum of neurodegeneration-related protein deposits for cross-reactivity, and by comparing the staining pattern of 9D5 with a generic Aβ antibody that targets a linear epitope (mAb NT244), and with another conformation-dependent Aβ antibody that selectively labels amyloid fibrils of various molecular weights (pAb OC). The 9D5 antibody does not cross-react with other aggregated protein deposits in brains of progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, Pick's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, frontotemporal lobar degeneration or amyotrophic lateral sclerosis with TDP-43 inclusions, Creutzfeldt-Jakob disease, and vessel changes in Binswanger encephalopathy, demonstrating the specificity of 9D5 for Aβ deposits. While NT244 and OC showed a comparable plaque load, 9D5 detected only approximately 15% of the total Aβ plaque load in the entorhinal cortex, the CA1 region, and the temporal neocortex. Our study further supports a possible therapeutic advantage of 9D5 by the highly specific recognition of an epitope found only in oligomeric assemblies of AβpE3 of AD patients. Moreover, selective binding to only a pathogenetically relevant fraction of Aβ deposits serves as rationale for passive immunization with 9D5-derivatives by limiting potential side effects of vaccination due to dissolvement of existing amyloid deposits.

Authors+Show Affiliations

Division of Molecular Psychiatry, Georg-August-University, University Medicine Göttingen, Göttingen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22232007

Citation

Venkataramani, Vivek, et al. "Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease Without Cross-reactivity With Other Protein Aggregates." Journal of Alzheimer's Disease : JAD, vol. 29, no. 2, 2012, pp. 361-71.
Venkataramani V, Wirths O, Budka H, et al. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. J Alzheimers Dis. 2012;29(2):361-71.
Venkataramani, V., Wirths, O., Budka, H., Härtig, W., Kovacs, G. G., & Bayer, T. A. (2012). Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. Journal of Alzheimer's Disease : JAD, 29(2), 361-71. https://doi.org/10.3233/JAD-2011-111379
Venkataramani V, et al. Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease Without Cross-reactivity With Other Protein Aggregates. J Alzheimers Dis. 2012;29(2):361-71. PubMed PMID: 22232007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. AU - Venkataramani,Vivek, AU - Wirths,Oliver, AU - Budka,Herbert, AU - Härtig,Wolfgang, AU - Kovacs,Gabor G, AU - Bayer,Thomas A, PY - 2012/1/11/entrez PY - 2012/1/11/pubmed PY - 2012/7/27/medline SP - 361 EP - 71 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 29 IS - 2 N2 - Recent evidence suggests that soluble oligomeric amyloid-β (Aβ) assemblies are critically involved in the pathogenesis of Alzheimer's disease (AD). We have generated a conformation-dependent monoclonal antibody (9D5) that selectively recognizes low-molecular weight AβpE3 oligomers, and demonstrated its diagnostic and therapeutic potential. Here, we further characterize the specificity of this antibody by evaluating a spectrum of neurodegeneration-related protein deposits for cross-reactivity, and by comparing the staining pattern of 9D5 with a generic Aβ antibody that targets a linear epitope (mAb NT244), and with another conformation-dependent Aβ antibody that selectively labels amyloid fibrils of various molecular weights (pAb OC). The 9D5 antibody does not cross-react with other aggregated protein deposits in brains of progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, Pick's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, frontotemporal lobar degeneration or amyotrophic lateral sclerosis with TDP-43 inclusions, Creutzfeldt-Jakob disease, and vessel changes in Binswanger encephalopathy, demonstrating the specificity of 9D5 for Aβ deposits. While NT244 and OC showed a comparable plaque load, 9D5 detected only approximately 15% of the total Aβ plaque load in the entorhinal cortex, the CA1 region, and the temporal neocortex. Our study further supports a possible therapeutic advantage of 9D5 by the highly specific recognition of an epitope found only in oligomeric assemblies of AβpE3 of AD patients. Moreover, selective binding to only a pathogenetically relevant fraction of Aβ deposits serves as rationale for passive immunization with 9D5-derivatives by limiting potential side effects of vaccination due to dissolvement of existing amyloid deposits. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/22232007/Antibody_9D5_recognizes_oligomeric_pyroglutamate_amyloid_β_in_a_fraction_of_amyloid_β_deposits_in_Alzheimer's_disease_without_cross_reactivity_with_other_protein_aggregates_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-2011-111379 DB - PRIME DP - Unbound Medicine ER -